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Abstract Massive intraventricular haemorrhage (IVH)
complicating aneurysmal subarachnoid haemorrhage
(SAH) is associated with a poor prognosis. Small obser-
vational studies suggest favourable results from ﬁbrinolysis
of the intraventricular blood. We performed an observa-
tional study on IVH in a large series of patients with SAH
to assess the proportion of patients that may beneﬁt from
ﬁbrinolytic treatment. From our prospective database we
retrieved patients with aneurysmal SAH admitted between
January 2000 and January 2005. We calculated the pro-
portion of patients with massive IVH and the proportion of
patients that are eligible for ﬁbrinolysis on basis of clinical
and CT-scan characteristics and assessed neurological
outcome in a treatment strategy without ﬁbrinolysis. Poor
neurological condition was deﬁned as World Federation of
Neurological Surgeons scale 4 and 5, poor outcome as
death or dependence 3 months after SAH. Of the 573
patients admitted with aneurysmal SAH, 59 (10%; 95%
conﬁdence interval CI 8–13%) had massive IVH, of which
55 were in poor clinical condition. For these 55 patients,
the case-fatality rate was 78% (95% CI 66–88%) and the
proportion with poor outcome 91% (95% CI 81–97%). Of
the 55 patients, 31 (56%, and 5% of all patients SAH
within the study period) fulﬁlled our eligibility criteria and
were considered suitable for intraventricular ﬁbrinolysis.
At 3 months, 30 of these 31 eligible patients (97%; 95% CI
85–100%) had a poor outcome. Massive IVH occurs in
10% of patients with aneurysmal SAH. Half of these
patients may beneﬁt from intraventricular ﬁbrinolysis.
Without ﬁbrinolysis outcome is almost invariably poor in
these patients.
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Introduction
Massive intraventricular haemorrhage (IVH) after aneu-
rysmal subarachnoid haemorrhage (SAH) is associated
with a poor prognosis, but there are few data on the pro-
portion of patients with massive IVH [11]. Approximately
85% of patients die within a few days if no treatment is
implemented. In patients treated with external ventricular
drainage (EVD) the case fatality rate is still close to 65%
[14]. Several small case series on ﬁbrinolysis of the intra-
ventricular blood suggest favourable results, but numbers
of treated and reported patients remain small [2, 3, 5, 12,
15, 19, 20]. The proportion of patients with aneurysmal
SAH that are eligible for intraventricular ﬁbrinolysis and
the potential health gain in this subset of patients are
unknown. We reviewed the records and radiographs of
patients with an aneurysmal SAH to study the proportion of
patients with severe IVH, the proportion of patients that in
our opinion are eligible for EVD and ﬁbrinolysis and the
outcome in these patients from a strategy without intra-
ventricular ﬁbrinolysis.
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Identiﬁcation of patients
Data from all patients with SAH admitted to our institution
are prospectively entered into a database. We retrieved
records of patients with aneurysmal SAH and IVH admit-
ted between January 2000 and January 2005. Patients were
included if the IVH was massive on admission or after
rebleeding. Massive IVH was deﬁned as a score of 7 or
higher on the Graeb scale [4]. This scale adds the indi-
vidual scores (maximum 12) for the lateral ventricles (1,
trace of blood or mild bleeding; 2, less than half of the
ventricle ﬁlled with blood; 3, more than half of the ven-
tricle ﬁlled with blood; 4, ventricle ﬁlled with blood and
expanded) and the third and fourth ventricles (1, blood
present, ventricle size normal; 2, ventricle ﬁlled with blood
and expanded).
Data collection
We extracted the following baseline data: age, sex, clinical
condition assessed by means of the World Federation of
Neurological Surgeons scale (WFNS) [1] score at admis-
sion and at time of rebleeding if the intraventricular
extension occurred after rebleeding, CT ﬁndings (amount
of intraventricular blood, intracerebral extension, bicaudate
index (BCI) [6, 18], presence of midline shift, aneurysm
location), clinical course during admission, and outcome
(Glasgow Outcome Scale) [8] at 3 months after SAH.
All three authors independently graded the amount of
intraventricular blood and assessed eligibility for EVD and
intraventricular ﬁbrinolysis. Within the subset of patients
with massive IVH we considered patients eligible for EVD
and ﬁbrinolysis if (1) patients were in poor clinical con-
dition (WFNS IV or V); (2) ventricles were enlarged; and
(3) no ICH was present that contributed to the poor clinical
condition, according to the judgment of the authors after
reviewing the CT scan. In case of conﬂicting opinions a
consensus meeting was held.
Outcome
Outcome status at 3 months after SAH had been assessed
by means of the Glasgow Outcome Scale (GOS). For the
present study we calculated the proportion of patients who
died and those with poor outcome (dead or dependent, i.e.
GOS 1–3).
Data analysis
Within the group of patients with an aneurysmal SAH we
calculated the proportion of patients with massive IVH and
the proportion of patients eligible for EVD and intraven-
tricular ﬁbrinolysis based on CT scan and clinical charac-
teristics. Furthermore, we calculated the proportion of
patients with poor outcome for the entire group of patients
with massive IVH and for the subgroup of patients who in
our opinion were eligible for EVD and ﬁbrinolysis.
Results
We identiﬁed 573 patients admitted with aneurysmal SAH,
59 (10%; 95% CI 8–13%) had massive IVH (Fig. 1). The
ages of the 59 patients ranged between 36 and 85 years
with a mean age of 57 years; 39 patients (66%) were
women. Of these 59 patients 16 had initially been admitted
with no or mild IVH, but developed massive IVH after
rebleeding. Seventeen patients (29%) had one or more
episodes of rebleeding during the following clinical course.
Four of the 59 patients (7%) had been admitted in a
good neurological condition and remained in good neuro-
logical condition during admission. The median Graeb-
score for these four patients was 7. They were independent
at 3 months after SAH. The other 55 patients with massive
Fig. 1 Flowchart of SAH patients. SAH subarachnoid haemorrhage,
IVH intraventricular haemorrhage, WFNS World Federation of
Neurological Surgeons scale, ICH intracerebral haemorrhage, EVD
external ventricular drainage
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Graeb-score was 9. Of the 59 patients, 25 did not fulﬁl our
predeﬁned eligibility criteria (good neurological condition
in four patients, accompanying ICH contributing to the
poor clinical condition in ten patients and no hydrocepha-
lus in 11 patients). Three patients who fulﬁlled the criteria
were considered ineligible nonetheless. Two of these
patients were deemed to have a poor outcome regardless of
treatment because of diffuse brain swelling with efface-
ment of the basal cisterns. In the third patient the distri-
bution of the IVH made the patient ineligible because the
third and fourth ventricle, as well as the occipital horns of
the lateral ventricles, were ﬁlled with blood, with no blood
in the frontal horns so that EVD without ﬁbrinolysis would
be the initial treatment of choice in our opinion. 31 out of
the 59 patients with massive IVH (53% of all patients with
severe IVH; 5% of all patients admitted with aneurysmal
SAH within the study period) fulﬁlled our predeﬁned eli-
gibility criteria and were considered suitable for EVD and
intraventricular ﬁbrinolysis.
CT scans demonstrated ICH in 28 patients (51%). These
were located in the frontal lobe in 20 patients, frontotem-
porally in two and in the temporal lobe in six patients. The
mean volume of the accompanying ICH in the patients
classiﬁed as eligible was 7.5 cm
3 (SD 5.7) compared to
54.6 cm
3 (SD 23.6) in the patients classiﬁed as not eligible
for intraventricular ﬁbrinolysis.
After 3 months, 50 out of the 55 patients (91%) had a
poor outcome. In 17 patients (31%) the aneurysm was
treated, in nine patients by means of neurosurgical clipping
and in eight patients by means of endovascular coiling. Of
the 31 patients that would have been eligible for EVD and
intraventricular ﬁbrinolysis, 13 patients (42%) had been
treated with EVD only. After 3 months, 24 of the 31
patients (77%) had died and 6 (19%) were left dependent.
Only one patient recovered to an independent state, this
patient had a WFNS score of IV and was treated with EVD.
Thus, 30 of the 31 patients (97%) considered eligible for
EVD and intraventricular ﬁbrinolysis had poor outcomes.
Discussion
In our cohort of patients, massive IVH occurred in 10% of
patients with aneurysmal SAH. Half of these patients
would have been eligible for EVD and intraventricular
ﬁbrinolysis according to our criteria on the basis of neu-
rological condition and CT-scan characteristics. All but one
of the eligible patients (97%) had a poor outcome after a
strategy without intraventricular ﬁbrinolysis.
Four patients with severe IVH remained in a good
neurological condition during admission and were inde-
pendent of help for activities of daily living 3 months after
the SAH. The good outcome in these patients conﬁrms our
opinion that these patients should not receive intraven-
tricular ﬁbrinolysis and should be excluded in future clin-
ical trials on intraventricular ﬁbrinolysis after aneurysmal
SAH.
The proportion of one out of three patients with reb-
leeding is higher than in series of SAH patients in general.
Possible explanations for this high proportion include a
longer exposure time because of postponement of treat-
ment of the ruptured aneurysm in these very poor-grade
patients. Furthermore, one-third of the patients in this
series developed massive IVH after a proven rebleeding,
and in the remaining patients out of hospital rebleeding
may have occurred in a considerable proportion, because
massive IVH is found more often in patients with reblee-
ding than in patients with a single bleed [9]. Thus, a large
proportion of the patients in our series had already had an
episode of rebleeding at study entry. Since a ﬁrst episode of
rebleeding is a risk factor for further episodes, this is
Table 1 Outcome and treatment characteristics of patients in poor neurological condition (WFNS IV or V)
Patients Death No.
of patients
Percent (95% CI) Death or dependent
No. of patients
Percent (95% CI)
All patients
n = 55 43 78 (66–88) 50 91 (81–97)
Patients eligible for intraventricular ﬁbrinolysis
n = 31 24 77 (60–90) 30 97 (85–100)
EVD ? (n = 13) 6 46 (21–73) 12 92 (68–100)
EVD – (n = 18) 18 100 (85–100) 18 100 (85–100)
Patients not eligible for intraventricular ﬁbrinolysis
n = 24 19 79 (60–92) 20 83 (65–94)
EVD ? (n = 7) 3 43 (12–78) 4 57 (22–88)
EVD – (n = 17) 16 94 (74–100) 16 94 (74–100)
WFNS World Federation of Neurological Surgeons scale, EVD external ventricular drainage
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123another explanation for the high proportion of patients with
rebleeding in our study [7].
The proportion of patients with massive IVH we found
is comparable with the 11% that was found before in a
cohort of 219 SAH patients [11]. Our results regarding
outcome are in concordance with the results found in a
systemic review in which 79% of patients with massive
IVH from aneurysmal SAH died and 93% had a poor
outcome, regardless of treatment with EVD or conser-
vative treatment. In this review, the reduction in case
fatality from 84 to 67% for patients treated with EVD
compared with conservative treatment was not statisti-
cally signiﬁcant and the poor outcome rates were similar
(93%) for both treatment strategies [14]. In our series we
cannot compare treatment with EVD with conservative
treatment because of selection bias. Treatment was not
according to a pre-speciﬁed protocol, but left at the
discretion of the treating physician or surgeon. Treatment
with EVD has probably been withheld in some patients
because of expected drain obstruction and poor outcome,
which may explain the small proportion of patients
treated with EVD. Withdrawal of care could have con-
tributed to the poor outcome rates. Especially in these
poor-grade patients, one should beware the possibility of
increasing poor outcome rates as a result of self-fulﬁlling
prophecy. Another limitation of our study is that the
assessment whether or not the accompanying ICH was a
major contributor to poor clinical condition was some-
what arbitrary. Even so, we feel that in patients with a
small accompanying ICH that does not importantly con-
tribute to poor clinical condition, its presence should not
be an absolute contraindication for intraventricular ﬁbri-
nolysis. EVD and intraventricular ﬁbrinolysis in primary
ICH accelerates the resolution of intraventricular blood
clots and seems to do so with a safety proﬁle similar to
that of EVD without ﬁbrinolysis [13].
An advantage of our study is that it describes a large
series of homogeneous patients. Most other articles
describe small numbers of patients with different under-
lying causes for the haemorrhage. The underlying cause is
of great importance for the prognosis [10, 16]. The amount
of IVH is a risk factor for poor outcome in patients with
IVH [11, 16, 17]. Because we dichotomised the amount of
blood we could not properly examine the exact relation
between the amount of blood and outcome. In addition, the
current study is the ﬁrst that describes outcome in the
subset of patients that would have been eligible for intra-
ventricular ﬁbrinolysis.
In conclusion, massive IVH is an important problem in
SAH. It occurs in 10% of patients, and half of these are
eligible for intraventricular ﬁbrinolysis. Without ﬁbrino-
lysis, outcome is almost invariably poor. With ﬁbrinolysis
it is unknown, although evidence that comes from small
case series suggests a clear beneﬁt. We must await results
from the CLEAR-IVH trial (Clot Lysis: Evaluating
Accelerated Resolution of Intraventricular Haemorrhage)
to clarify the effectiveness of intraventricular ﬁbrinolysis in
IVH after ICH. Likewise, an RCT that assesses intraven-
tricular ﬁbrinolysis in poor-grade aneurysmal SAH patients
is clearly warranted, considering the very high poor out-
come rates in these patients, even when treated with EVD.
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